Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome

JAMA: The Journal of the American Medical Association

Volumn 269, Issue 14, 1993, Pages 1829-1835

  Dinarello, Charles A ^a   Gelfand, Jeffrey A ^a   Wolff, Sheldon M ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 8; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR;

ARTICLE; HOST RESISTANCE; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING;

ANIMAL; CYTOKINES; HUMAN; IMMUNOTHERAPY; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-8; RECEPTORS, INTERLEUKIN-1; SEPTICEMIA; SIALOGLYCOPROTEINS; SUPPORT, U.S. GOV'T, P.H.S.; SYNDROME; TUMOR NECROSIS FACTOR;

EID: 0027528798     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1993.03500140081040     Document Type: Article

References (84)

1. Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA. 1992;268:3452-3455.
2. Billiau A, Vandekerckhove F. Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest. 1991;21:559-573.
3. Biancone L, Tetta C, Turello E, et al. Platelet-activating factor biosynthesis by cultured mesangial cells is modulated by proteinase inhibitors. J Am Soc Nephrol. 1992;2:1251-1261.
4. Baggiolini M, Dewald B, Waltz A. Interleukin-8 and related cytokines. In: Gallin JI, Goldstein IM, Synderman R, eds. Inflammation: Basic Principles and Clinical Correlates. New York, NY: Raven Press; 1992:247-263.
5. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986;163:1433-1450.
6. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988;81:1162-1172.
7. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985;162:2163-2168.
8. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987;316:379-385.
9. Perlmutter DH, Dinarello CA, Punsal PI, Colten HR. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest. 1986;78:1349-1354.
10. Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987;5:1942-1951.
11. Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol. 1989;44:153-205.
12. Smith JW II, Urba W, Steis R, et al. Interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol. 1992;10:1141-1152.
13. van der Poll T, Bueller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 1990;322:1622-1627.
14. Fischer E, Marano MA, Barber AE, et al. A comparison between the effects of interleukin-1α administration and sublethal endotoxemia in primates. Am J Physiol. 1991;261:R442-R449.
15. Arend WP. Interleukin 1 receptor antagonist: a new member of the interleukin family. J Clin Invest. 1991;88:1445-1451.
16. Christman JW. Potential treatment of sepsis syndrome with cytokine-specific agents. Chest. 1992; 102:613-617.
17. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993;328:106-113.
18. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 1991;77:1627-1652.
19. Mandrup-Poulsen T, Bendtzen K, Dinarello CA, Nerup J. Potentiation of IL-1 mediated B-cell killing by TNF: human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. J Immunol. 1987;139:4077-4082.
20. Walsh CE, Liu JM, Anderson SM, Rossio JL, Nienhuis AW, Young NS. A trial of recombinant human interleukin-1 in patients with severe refractory aplastic anemia. Br J Haematol. 1992;80:106-110.
21. van der Poll T, van Deventer S, Hack CE, et al. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood. 1992;79: 693-698.
22. Calandra T, Baumgartner JD, Grau GE, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock: Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis. 1990;161:982-987.
23. Hack CE, DeGroot ER, Felt-Bersma RJF, et al. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989;74:1704-1710.
24. Dinarello CA. Role of interleukin-1 in infectious diseases. Immunol Rev. 1992;127:119-146.
25. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318: 1481-1486.
26. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis. 1990;161:79-84.
27. Cannon JG, Friedberg JS, Gelfand JA, Tompkins RG, Burke JF, Dinarello CA. Circulating interleukin-1β and tumor necrosis factor-α after burn injury in humans. Crit Care Med. 1992;20:1414-1419.
28. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine: evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990;265:1531-1536.
29. Barak V, Peritt D, Flechner I, et al. The IL-1 specific inhibitor from the M20 cell line is distinct from the IL-1 receptor antagonist. Lymphokine Cytokine Res. 1991;10:437-442.
30. Seckinger P, Lowenthal JW, Williamson K, Dayer JM, MacDonald HR. A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol. 1987;139:1546-1549.
31. Symons JA, Eastgate JA, Duff GW. Purification and characterization of a novel soluble receptor for interleukin-1. J Exp Med. 1991;174:1251-1254.
32. van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α in vitro and in vivo. Proc Natl Acad Sci U S A. 1992;89:4845-4849.
33. Porat R, Poutsiaka DD, Miller LC, Granowitz EV, Dinarello CA. Interleukin-1 (IL-1) receptor blockade reduces endotoxin and Borrelia burgdorferi-stimulated IL-8 synthesis in human mononuclear cells. FASEB J. 1992;6:2482-2486.
34. Dejana E, Breviario F, Erroi A, et al. Modulation of endothelial cell functions by different molecular species of interleukin 1. Blood. 1987;69:695-969.
35. Mizoguchi Y, Ichikawa Y, Kioka K, Kawada N, Kobayashi K, Yamamoto S. Effects of arachidonic acid metabolites and interleukin-1 on platelet activating factor production by hepatic sinusoidal endothelial cells from mice. J Gastroenterol Hepatol. 1991;6:283-288.
36. Raz A, Wyche A, Siegel N, Needleman P. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J Biol Chem. 1988;263:3022-3028.
37. Beasley D, Schwartz JH, Brenner BM. Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest. 1991;87:602-608.
38. Ikejima T, Okusawa S, van der Meer JW, Dinarello CA. Induction by toxic-shock-syndrome toxin-1 of a circulating tumor necrosis factor-like substance in rabbits and of immunoreactive tumor necrosis factor and interleukin-1 from human mononuclear cells. J Infect Dis. 1988;158:1017-1025.
39. Hackett SP, Stevens DL. Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis. 1992;165:879-885.
40. Beutler B, Milsark IW, Cerami A. Passive immunization against cachetin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985;229:869-871.
41. Tracey K, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature. 1987;330:662-664.
42. Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest. 1988;81:1925-1937.
43. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990;348:550-552.
44. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA. A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotoxemia in mice. J Exp Med. 1991;173: 1029-1032.
45. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock. FASEB J. 1991;5:338-343.
46. Fischer E, Marano MA, van Zee KJ, et al. IL-1 receptor blockade improves survival and hemodynamic performance in E coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest. 1992;89:1551-1557.
47. Van Damme J, De Ley M, Opdenakker G, Billiau A, De Somer P. Homogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1. Nature. 1985;314:266-268.
48. van der Poll T, Romijn JA, Wiersinga WM, Sauerwein HP. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metabol. 1990;71:1567-1571.
49. Tewari A, Buhles WC Jr, Starnes HF Jr. Preliminary report: effects of interleukin-1 on platelet counts. Lancet. 1990;336:712-714.
50. Knudsen PJ, Dinarello CA, Strom TB. Gluco-corticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol. 1987;139:4129-4134.
51. McCartney FN, Mizel D, Wong H, Wahl L, Wahl S. TGF-beta regulates production of growth factors and TGF-beta by human peripheral blood monocytes. Growth Factors. 1990;4:27-35.
52. Howard M, O’Garra A, Ishida H, de Waal Malefyt R, de Vries J. Biological properties of interleukin 10. J Clin Immunol. 1992;12:239-247.
53. Vannier E, Miller LC, Dinarello CA. Coordinated anti-inflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Nati Acad Sci U S A. 1992;89:4076-4080.
54. Streiter RM, Remick PA, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988;155:1230-1236.
55. Fanslow WC, Sims JE, Sassenfeld H, et al. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science. 1990;248:739-742.
56. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989;264:11974-11980.
57. Gershenwald JE, Fong YM, Fahey TJ III, et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA. 1990;87:4966-4970.
58. Cerretti DP, Kozlosky C, Mosley B, et al. Molecular cloning of the interleukin-1 beta converting enzyme. Science. 1992;256:97-100.
59. Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992;356:768-774.
60. Dinarello CA, Thompson RC. Blocking IL-1: effects of IL-1 receptor antagonist in vitro and in vivo. Immunol Today. 1991;12:404-410.
61. Aiura K, Gelfand JA, Wakabayashi G, et al. Interleukin-1 receptor antagonist blocks staphylococcal induced shock in rabbits. Cytokine. 1991;3: 498.
62. Fisher CJJ, Slotman GJ, Opal S, et al. Interleukin-1 receptor antagonist reduces mortality in patients with sepsis syndrome. Presented at the fourth annual meeting of the American College of Chest Physicians; November 4,1991; San Francisco, Calif.
63. Granowitz EV, Porat R, Mier JW, et al. Pharmacokinetics, safety, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 1992;4: 353-360.
64. Granowitz EV, Santos A, Poutsiaka DD, et al. Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans. Lancet. 1991;338:1423-1424.
65. Fischer E, Van Zee KJ, Marano MA, et al. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood. 1992;79:2196-2200.
66. Rambaldi A, Torcia M, Bettoni S, et al. Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood. 1991;78:3248-3253.
67. Miller LC, Lynch EA, Isa S, Logan JW Dinarello CA, Steere AC. Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet. 1993;341:146-148.
68. Mancilla J, Garcia P, Dinarello CA. IL-1 receptor antagonist can either protect or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect Immun. In press.
69. Lesslauer W, Tabuchi H, Gentz M, et al. Recombinant soluble TNF receptor proteins inhibit LPS-induced lethality in mice. Cytokine. 1991;3: 497.
70. Ulich TR, Yin SM, Guo KZ, del Castillo J, Eisenberg SP, Thompson RC. The intratracheal administration of endotoxin and cytokines, III: the interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation. Am J Pathol. 1991;138:521-524.
71. Henricson BE, Neta R, Vogel SN. An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance. Infect Immun. 1991; 59:1188-1191.
72. McCarthy PL, Abhyankar S, Neben S, et al. Inhibition of interleukin-1 by interleukin-1 receptor antagonist prevents graft versus host disease. Blood. 1991;78:1915-1918.
73. Engelmann H, Holtmann H, Brakebusch C, et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem. 1990;265:14497-14504.
74. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol. 1991;21: 2883-2886.
75. Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia. J Clin Invest. 1992;90:533-536.
76. Shapiro L, Clark BD, Orencole SF, Poutsiaka DD, Granowitz EV, Dinarello CA. Detection of tumor necrosis factor soluble receptor p55 (TNFs-Rp55) in blood samples from healthy and endotoxemic humans. J Infect Dis. In press.
77. Aderka D, Engelmann H, Hornik V, et al. Increased serum levels of soluble receptors for tumor necrosis in cancer patients. Cancer Res. 1991;51: 5602-5607.
78. Herve P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood. 1992; 79:3362-3368.
79. van der Meer JWM, Barza M, Wolff SM, Dinarello CA. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Nati Acad Sci U S A. 1988; 85:1620-1623.
80. Wallach D, Holtmann H, Engelmann H, Nophar Y. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol. 1988;140:2994-2999.
81. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol. 1992;148:2724-2730.
82. Bromberg JS, Chavin KD, Kunkel SL. Anti-tumor necrosis factor antibodies suppress cell-mediated immunity in vivo. J Immunol. 1992;148:3412-3417.
83. Havell EA, Moldawer LL, Helfgott D, Kilian PL, Sehgal PB. Type I IL-1 receptor blockade exacerbates murine listeriosis. J Immunol. 1992;148: 1486-1492.
84. Fisher CJ Jr, Dhalnaut J-F, Pribble JP, Knaus WA, and the IL-1 Receptor Antagonist Study Group. A study evaluating the safety and efficacy of human recombinant interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Presented at the 13th International Symposium on Intensive Care and Emergency Medicine; March 23, 1993; Brussels, Belgium.